Intra-Cellular Therapies (NASDAQ:ITCI) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.
Several other analysts also recently weighed in on ITCI. Royal Bank of Canada began coverage on shares of Intra-Cellular Therapies in a research report on Thursday, February 8th. They set an “outperform” rating and a $33.00 price objective for the company. Zacks Investment Research downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research report on Tuesday, October 17th. ValuEngine downgraded shares of Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Canaccord Genuity began coverage on shares of Intra-Cellular Therapies in a research report on Friday, December 15th. They set a “buy” rating and a $31.00 price objective for the company. Finally, SunTrust Banks upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research report on Wednesday, November 8th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $26.70.
Shares of Intra-Cellular Therapies (ITCI) opened at $19.19 on Tuesday. The firm has a market cap of $1,050.00, a P/E ratio of -8.76 and a beta of 0.87. Intra-Cellular Therapies has a 12-month low of $7.85 and a 12-month high of $22.67.
Institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. acquired a new position in shares of Intra-Cellular Therapies in the 3rd quarter valued at $101,000. Quantbot Technologies LP increased its stake in Intra-Cellular Therapies by 233.1% in the 3rd quarter. Quantbot Technologies LP now owns 8,614 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 6,028 shares during the period. SG Americas Securities LLC increased its stake in Intra-Cellular Therapies by 45.9% in the 3rd quarter. SG Americas Securities LLC now owns 12,060 shares of the biopharmaceutical company’s stock valued at $190,000 after buying an additional 3,794 shares during the period. Voya Investment Management LLC increased its stake in Intra-Cellular Therapies by 16.0% in the 2nd quarter. Voya Investment Management LLC now owns 16,911 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 2,338 shares during the period. Finally, Teacher Retirement System of Texas acquired a new position in Intra-Cellular Therapies in the 4th quarter valued at $212,000. 74.77% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This story was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://stocknewstimes.com/2018/02/15/bidaskclub-upgrades-intra-cellular-therapies-itci-to-sell.html.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.